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background:  Immature platelets contain mRNA that is translationally active, they can be easily detected using a hematoanalyzer and are 
known to be less responsive to the effects of antiplatelet drugs. The purpose of this study was to determine the prognostic significance of elevated 
immature platelet count (IPC) in patients with coronary artery disease (CAD).
methods: The study was a prospective cohort of patients with CAD. On enrollment patients underwent platelet aggregation studies and 
measurement of the IPC. Patients were then followed for the composite end point of death, myocardial infarction, revascularization, or hospitalization 
for angina. Events were adjudicated by two independent investigators blinded to IPC.
results: Eighty nine patients were followed for a median of 31 months. Patients were stratified into tertiles according to their IPC. Patients in the 
upper tertile had higher rates of the primary outcome compared to the mid, and lower tertiles (60% vs. 24% vs. 16%, respectively; p=0.001). After 
adjusting for age, admission diagnosis, index revascularization (PCI or CABG), and ejection fraction, patients in the upper IPC tertile were more likely 
to suffer the composite outcome (HR 7.9, 95%CI 2.6-23; p<0.001).
Conclusions: IPC is a novel biomarker for risk stratifying patients with coronary artery disease for adverse clinical events , it is readily available as 
part of complete blood count. Future studies should focus on utilization of this marker for individualized antiplatelet therapy.
 
